These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 604096)

  • 1. Dynamics and specificity of influenza virus antibodies as well as IgE values in serum and nasal fluid after repeated local application of live bivalent influenza vaccine.
    Werner J; Kuwert EK
    Dev Biol Stand; 1977 Jun 1-3; 39():135-40. PubMed ID: 604096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on sensitization after repeated topic application of live attenuated influenza vaccine (Gripovax) (author's transl)].
    Werner J; Kuwert EK
    Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):144-54. PubMed ID: 315676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretory immune response after nasal vaccination with live attenuated influenza viruses.
    Crifö S; Vella S; Filiaci F; Resta S; Rocchi G
    Rhinology; 1980 Jun; 18(2):87-92. PubMed ID: 7403787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
    Kuwert EK; Höher PG; Werner J; Scheiermann N; Thraenhart O; Müller B; Kleber G
    Dev Biol Stand; 1977 Jun 1-3; 39():77-83. PubMed ID: 604137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa.
    Brokstad KA; Eriksson JC; Cox RJ; Tynning T; Olofsson J; Jonsson R; Davidsson A
    J Infect Dis; 2002 Apr; 185(7):878-84. PubMed ID: 11920311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM; Camilloni B; Basileo M; Neri M; Lepri E; Spighi M
    Gerontology; 2007; 53(6):411-8. PubMed ID: 17975317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune response to influenza vaccines.
    Ghendon Y
    Acta Virol; 1990 May; 34(3):295-304. PubMed ID: 1980401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tolerance and immunogenicity of an attenuated live influenza virus vaccine in man (author's transl)].
    Kuwert E; Höher PG; Fröcher R; Marcus I; Thraenhart O
    Dtsch Med Wochenschr; 1975 Dec; 100(52):2629-35. PubMed ID: 1204500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of resistance to influenza virus infection in animal models.
    Potter CW; McLaren C; Jennings R
    Dev Biol Stand; 1975; 28():307-18. PubMed ID: 1126574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral influenza vaccination with live attenuated viruses. 1. Acceptability, immunogenicity and transmissibility.
    Petrilli FL; Crovari P; Cuneo-Crovari P; Badolati G; Canepa R
    Boll Ist Sieroter Milan; 1975 Oct; 54(4):312-22. PubMed ID: 1203087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaphylaxis from the influenza virus vaccine.
    Coop CA; Balanon SK; White KM; Whisman BA; Rathkopf MM
    Int Arch Allergy Immunol; 2008; 146(1):85-8. PubMed ID: 18087166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination.
    Kitikoon P; Nilubol D; Erickson BJ; Janke BH; Hoover TC; Sornsen SA; Thacker EL
    Vet Immunol Immunopathol; 2006 Aug; 112(3-4):117-28. PubMed ID: 16621020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live attenuated influenza virus vaccines in patients with chronic broncho-pulmonary diseases. Clinical and immunological evaluation.
    Prevost JM; Vereerstraeten-Schmerber J; Lamy F; De Koster JP
    Scand J Respir Dis; 1975 May; 56(1):58-69. PubMed ID: 1096297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of immunoglobulins and antibodies to haemaglutinin and neuraminidase of influenza virus in nasal secretions after natural infection.
    Hrusková J; Syrůcek L; Tůmová B; Stumpa A; Brůcková M; Losová M; Berkovicová V
    Acta Virol; 1976 Apr; 20(2):126-34. PubMed ID: 5867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of an inhibitor-resistant live attenuated influenza vaccine in normal and asthmatic adults.
    Warshauer DM; Minor TE; Inhorn SL; Reed CE; Dick EC
    Dev Biol Stand; 1976; 33():184-90. PubMed ID: 782967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice.
    Hovden AO; Cox RJ; Madhun A; Haaheim LR
    Scand J Immunol; 2005 Oct; 62(4):342-52. PubMed ID: 16253121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
    Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.